Storia in 8 fonti

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

Raccontata da

healio.com

fiercepharma.com

economictimes.indiatimes.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

morningstar.comStai leggendo3 mesi fa

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery…

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

originale

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

Confronto fonti

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery…

Timeline cronologica

‘Thrilling’: Regimen reduces metastasis, recurrence in high-risk prostate cancer

ASCO: J&J breaks the prostate cancer treatment mold with fresh Erleada ph. 3 win

J&J's Erleada study succeeds in early-stage prostate cancer, but questions remain

Johnson & Johnson prostate cancer drug reduces risk of cancer spread and death in late-stage study

‘Thrilling’: Regimen reduces metastasis, recurrence in high-risk prostate cancer

Prostate cancer breakthrough as drug combo gives patients a powerful new chance

ASCO: J&J breaks the prostate cancer treatment mold with fresh Erleada ph. 3 win

Johnson & Johnson prostate cancer drug reduces risk of cancer spread and death in late-stage study

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of…

Practice-Changing Trial in Prostate Cancer Shows Benefits of Perioperative Therapy

Prostate cancer breakthrough as drug combo gives patients a powerful new chance

J&J's Erleada study succeeds in early-stage prostate cancer, but questions remain

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer reduces risk of metastasis, death

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery…

Timeline cronologica

‘Thrilling’: Regimen reduces metastasis, recurrence in high-risk prostate cancer

ASCO: J&J breaks the prostate cancer treatment mold with fresh Erleada ph. 3 win

J&J's Erleada study succeeds in early-stage prostate cancer, but questions remain

Johnson & ​Johnson prostate cancer drug reduces risk of cancer spread and death in late-stage study

‘Thrilling’: Regimen reduces metastasis, recurrence in high-risk prostate cancer

Prostate cancer breakthrough as drug combo gives patients a powerful new chance

ASCO: J&J breaks the prostate cancer treatment mold with fresh Erleada ph. 3 win

Johnson & ​Johnson prostate cancer drug reduces risk of cancer spread and death in late-stage study

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of…

Practice-Changing Trial in Prostate Cancer Shows Benefits of Perioperative Therapy

Prostate cancer breakthrough as drug combo gives patients a powerful new chance

J&J's Erleada study succeeds in early-stage prostate cancer, but questions remain

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer reduces risk of metastasis, death

Johnson & Johnson prostate cancer drug reduces risk of cancer spread and death in late-stage study

Johnson & Johnson prostate cancer drug reduces risk of cancer spread and death in late-stage study